Trials / Completed
CompletedNCT02824003
Study to Evaluate the Effect of ISIS GCGRRx on Hepatic Lipid and Glycogen Content in Type 2 Diabetes
Double Blind, Randomized, Placebo-Controlled, Phase 2A Mechanistic Study to Evaluate the Effect of ISIS 449884 (ISIS-GCGRRx) on Hepatic Lipid and Glycogen Content in Patients With Type 2 Diabetes Being Treated With Metformin
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Ionis Pharmaceuticals, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effect of ISIS 449884 (ISIS-GCGRRX) on Hepatic Lipid and Glycogen Content in patients with Type 2 Diabetes being treated with Metformin.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ISIS-GCGRRx | once weekly dosing for 13 weeks |
| DRUG | Placebo | once weekly dosing for 13 weeks |
Timeline
- Start date
- 2016-04-01
- Primary completion
- 2016-12-15
- Completion
- 2017-05-22
- First posted
- 2016-07-06
- Last updated
- 2018-05-08
Locations
1 site across 1 country: Austria
Source: ClinicalTrials.gov record NCT02824003. Inclusion in this directory is not an endorsement.